Find Ozenoxacin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 245765-41-7, Xepi, T-3912, T 3912, 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic acid, Gf-001001-00
Molecular Formula
C21H21N3O3
Molecular Weight
363.4  g/mol
InChI Key
XPIJWUTXQAGSLK-UHFFFAOYSA-N
FDA UNII
V0LH498RFO

Ozenoxacin
To date, ozenoxacin has been used in trials studying the treatment of impetigo. As of December 11, 2017 the FDA approved Ferrer Internacional S.A.'s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age and older. Despite being a common and highly contagious bacerial skin infection that affects millions of children and adults in the United States each year, ozenoxacin cream is a novel, non-fluorinated quinolone that has demonstrated safe and effective therapy in both the adult and pediatric population.
Ozenoxacin is a Quinolone Antimicrobial.
1 2D Structure

Ozenoxacin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic acid
2.1.2 InChI
InChI=1S/C21H21N3O3/c1-11-8-13(9-23-20(11)22-3)15-6-7-16-18(12(15)2)24(14-4-5-14)10-17(19(16)25)21(26)27/h6-10,14H,4-5H2,1-3H3,(H,22,23)(H,26,27)
2.1.3 InChI Key
XPIJWUTXQAGSLK-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=CC(=CN=C1NC)C2=C(C3=C(C=C2)C(=O)C(=CN3C4CC4)C(=O)O)C
2.2 Other Identifiers
2.2.1 UNII
V0LH498RFO
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid

2. Ozanex

3. Xepi

2.3.2 Depositor-Supplied Synonyms

1. 245765-41-7

2. Xepi

3. T-3912

4. T 3912

5. 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic Acid

6. Gf-001001-00

7. V0lh498rfo

8. 1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)pyridin-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

9. Ozenoxacin Cream

10. Ozenoxacin [inn]

11. Ozenoxacin [inn:jan]

12. Unii-v0lh498rfo

13. Ozadub

14. Xepi (tn)

15. Ozenoxacin [mi]

16. Ozenoxacin; T-3912

17. Ozenoxacin [jan]

18. Ozenoxacin [usan]

19. Ozenoxacin [who-dd]

20. Ozenoxacin (jan/usan/inn)

21. Schembl1711829

22. Chembl3990047

23. Ozenoxacin [orange Book]

24. Gtpl10841

25. Dtxsid00947446

26. Chebi:136050

27. Bcp16621

28. Ex-a2693

29. Vja76541

30. Who 8788

31. Zinc1483896

32. S6582

33. Akos032947315

34. At18754

35. Db12924

36. Sb16801

37. Ncgc00532517-01

38. Bs-16742

39. Da-31712

40. Hy-14957

41. Ozenoxacin 100 Microg/ml In Acetonitrile

42. Cs-0003657

43. Ft-0701296

44. D09544

45. Q17125399

46. Gf-001001-00; M-5120; T-3912; Gf-00100100;t3912;t 3912

47. 1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid

48. 3-quinolinecarboxylic Acid, 1-cyclopropyl-1,4-dihydro-8-methyl-7-(5-methyl-6-(methylamino)-3-pyridinyl)-4-oxo-

2.4 Create Date
2006-10-25
3 Chemical and Physical Properties
Molecular Weight 363.4 g/mol
Molecular Formula C21H21N3O3
XLogP34.1
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count4
Exact Mass363.15829154 g/mol
Monoisotopic Mass363.15829154 g/mol
Topological Polar Surface Area82.5 Ų
Heavy Atom Count27
Formal Charge0
Complexity645
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Ozenoxacin cream is indicated for the topical treatment of impetigo caused by *Staphylococcus aureus* or *Streptococcus pyogenes* in patients aged 2 months of age and older.


FDA Label


Treatment of impetigo


5 Pharmacology and Biochemistry
5.1 Pharmacology

Although the exposure response relationship for ozenoxacin after it has been applied topically has not yet been studied, a formal relationship is unlikely because systemic exposure of ozenoxacin following its topical application has been measured to be negligible.


5.2 MeSH Pharmacological Classification

Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)


Topoisomerase Inhibitors

Compounds that inhibit the activity of DNA TOPOISOMERASES. (See all compounds classified as Topoisomerase Inhibitors.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
OZENOXACIN
5.3.2 FDA UNII
V0LH498RFO
5.3.3 Pharmacological Classes
Quinolones [CS]; Quinolone Antimicrobial [EPC]
5.4 ATC Code

D - Dermatologicals

D06 - Antibiotics and chemotherapeutics for dermatological use

D06A - Antibiotics for topical use

D06AX - Other antibiotics for topical use

D06AX14 - Ozenoxacin


5.5 Absorption, Distribution and Excretion

Absorption

Four studies were performed in which varying strengths of ozenoxacin cream, up to 2% (twice the concentration of the marketed formulation), were administered to 110 patients. Three of the studies examined systemic absorption in healthy subjects and in subjects having impetigo. The studies were performed with either single or repeated application of up to 1 g ozenoxacin cream to intact or abraded skin (up to 200 cm squared surface area). No systemic absorption was seen in 84 of 86 subjects, and negligible systemic absorption was seen at the level of detection (0.489 ng/mL) in 2 subjects.


Route of Elimination

Studies regarding elimination and excretion have not yet been investigated in humans due to the negligible systemic absorption observed in clinical studies.


Volume of Distribution

Ozenoxacin undergoes negligible systemic absorption after its topical administration. Subsequently, since negligible systemic absorption of ozenoxacin was observed in clinical studies, tissue distribution has not been investigated in humans either.


Clearance

Ozenoxacin undergoes negligible systemic absorption after its topical administration.


5.6 Metabolism/Metabolites

Studies have demonstrated that ozenoxacin is not metabolized in the presence of fresh human skin discs and is minimally metabolized in human hepatocytes.


5.7 Mechanism of Action

Ozenoxacin is a quinolone antibiotic drug. And, like most quinolones, ozenoxacin predominately executes its mechanism of action by entering into bacterial cells and acting to inhibit the bacterial DNA replication enzymes DNA gyrase A and topoisomerase IV. As DNA gyrase A and topoisomerase IV are essential to bacterial DNA replication activities including supercoiling, supercoil relaxation, chromosomal condensation, chromosomal decatenation and more, their inhibition is the principal action of ozenoxacin's mechanism and it has been demonstrated to be bactericidal against *S. aureus* and *S. pyogenes* organisms.


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 245765-41-7 / Ozenoxacin API manufacturers, exporters & distributors?

Ozenoxacin manufacturers, exporters & distributors 1

51

PharmaCompass offers a list of Ozenoxacin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ozenoxacin manufacturer or Ozenoxacin supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ozenoxacin manufacturer or Ozenoxacin supplier.

PharmaCompass also assists you with knowing the Ozenoxacin API Price utilized in the formulation of products. Ozenoxacin API Price is not always fixed or binding as the Ozenoxacin Price is obtained through a variety of data sources. The Ozenoxacin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Ozenoxacin

Synonyms

245765-41-7, Xepi, T-3912, T 3912, 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)pyridin-3-yl]-4-oxoquinoline-3-carboxylic acid, Gf-001001-00

Cas Number

245765-41-7

Unique Ingredient Identifier (UNII)

V0LH498RFO

About Ozenoxacin

To date, ozenoxacin has been used in trials studying the treatment of impetigo. As of December 11, 2017 the FDA approved Ferrer Internacional S.A.'s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age and older. Despite being a common and highly contagious bacerial skin infection that affects millions of children and adults in the United States each year, ozenoxacin cream is a novel, non-fluorinated quinolone that has demonstrated safe and effective therapy in both the adult and pediatric population.

245765-41-7 Manufacturers

A 245765-41-7 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 245765-41-7, including repackagers and relabelers. The FDA regulates 245765-41-7 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 245765-41-7 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of 245765-41-7 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

245765-41-7 Suppliers

A 245765-41-7 supplier is an individual or a company that provides 245765-41-7 active pharmaceutical ingredient (API) or 245765-41-7 finished formulations upon request. The 245765-41-7 suppliers may include 245765-41-7 API manufacturers, exporters, distributors and traders.

click here to find a list of 245765-41-7 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

245765-41-7 USDMF

A 245765-41-7 DMF (Drug Master File) is a document detailing the whole manufacturing process of 245765-41-7 active pharmaceutical ingredient (API) in detail. Different forms of 245765-41-7 DMFs exist exist since differing nations have different regulations, such as 245765-41-7 USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A 245765-41-7 DMF submitted to regulatory agencies in the US is known as a USDMF. 245765-41-7 USDMF includes data on 245765-41-7's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 245765-41-7 USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of 245765-41-7 suppliers with USDMF on PharmaCompass.

245765-41-7 JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The 245765-41-7 Drug Master File in Japan (245765-41-7 JDMF) empowers 245765-41-7 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the 245765-41-7 JDMF during the approval evaluation for pharmaceutical products. At the time of 245765-41-7 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of 245765-41-7 suppliers with JDMF on PharmaCompass.

245765-41-7 KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a 245765-41-7 Drug Master File in Korea (245765-41-7 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 245765-41-7. The MFDS reviews the 245765-41-7 KDMF as part of the drug registration process and uses the information provided in the 245765-41-7 KDMF to evaluate the safety and efficacy of the drug.

After submitting a 245765-41-7 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 245765-41-7 API can apply through the Korea Drug Master File (KDMF).

click here to find a list of 245765-41-7 suppliers with KDMF on PharmaCompass.

245765-41-7 WC

A 245765-41-7 written confirmation (245765-41-7 WC) is an official document issued by a regulatory agency to a 245765-41-7 manufacturer, verifying that the manufacturing facility of a 245765-41-7 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 245765-41-7 APIs or 245765-41-7 finished pharmaceutical products to another nation, regulatory agencies frequently require a 245765-41-7 WC (written confirmation) as part of the regulatory process.

click here to find a list of 245765-41-7 suppliers with Written Confirmation (WC) on PharmaCompass.

245765-41-7 NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 245765-41-7 as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for 245765-41-7 API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture 245765-41-7 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain 245765-41-7 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 245765-41-7 NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of 245765-41-7 suppliers with NDC on PharmaCompass.

245765-41-7 GMP

245765-41-7 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of 245765-41-7 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 245765-41-7 GMP manufacturer or 245765-41-7 GMP API supplier for your needs.

245765-41-7 CoA

A 245765-41-7 CoA (Certificate of Analysis) is a formal document that attests to 245765-41-7's compliance with 245765-41-7 specifications and serves as a tool for batch-level quality control.

245765-41-7 CoA mostly includes findings from lab analyses of a specific batch. For each 245765-41-7 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

245765-41-7 may be tested according to a variety of international standards, such as European Pharmacopoeia (245765-41-7 EP), 245765-41-7 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (245765-41-7 USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty